Comments
Loading...

Bioventus

BVSNASDAQ
$7.17
00.00%
Last update: Jul 19, 4:00 PM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$9.00
Lowest Price Target1
$2.50
Consensus Price Target1
$6.13

Bioventus (NASDAQ:BVS) Stock, Analyst Ratings, Price Targets, Forecasts

Bioventus Inc has a consensus price target of $6.13 based on the ratings of 6 analysts. The high is $9 issued by Craig-Hallum on March 13, 2024. The low is $2.5 issued by Goldman Sachs on November 30, 2022. The 3 most-recent analyst ratings were released by Canaccord Genuity, Craig-Hallum, and Canaccord Genuity on May 8, 2024, March 13, 2024, and December 7, 2023, respectively. With an average price target of $8 between Canaccord Genuity, Craig-Hallum, and Canaccord Genuity, there's an implied 11.50% upside for Bioventus Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Canaccord Genuity
Craig-Hallum
Goldman Sachs
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for Bioventus

Buy NowGet Alert
05/08/2024Buy Now11.5%Canaccord Genuity
William Plovanic
$7 → $8MaintainsBuyGet Alert
03/13/2024Buy Now25.44%Craig-Hallum
Alexander Nowak
$6 → $9MaintainsBuyGet Alert
12/07/2023Buy Now-2.44%Canaccord Genuity
William Plovanic
$3.66 → $7UpgradeHold → BuyGet Alert
04/03/2023Buy Now-30.31%Craig-Hallum
Alexander Nowak
$10 → $5MaintainsHoldGet Alert
11/30/2022Buy Now-65.16%Goldman Sachs
Amit Hazan
$13 → $2.5MaintainsNeutralGet Alert
11/22/2022Buy NowCraig-Hallum
Alexander Nowak
DowngradeBuy → HoldGet Alert
11/10/2022Buy Now-30.31%Morgan Stanley
Drew Ranieri
$11 → $5MaintainsOverweightGet Alert
11/09/2022Buy NowCanaccord Genuity
Kyle Rose
DowngradeBuy → HoldGet Alert
11/09/2022Buy NowJP Morgan
Robbie Marcus
DowngradeOverweight → UnderweightGet Alert
10/11/2022Buy Now53.31%Morgan Stanley
Drew Ranieri
$12 → $11MaintainsOverweightGet Alert
09/07/2022Buy Now81.18%Goldman Sachs
Amit Hazan
$15 → $13MaintainsNeutralGet Alert
08/12/2022Buy Now67.25%Morgan Stanley
Drew Ranieri
$11 → $12MaintainsOverweightGet Alert
05/12/2022Buy Now53.31%Morgan Stanley
Drew Ranieri
$18 → $11MaintainsOverweightGet Alert
03/21/2022Buy Now136.93%Goldman Sachs
Amit Hazan
$19 → $17MaintainsNeutralGet Alert
03/15/2022Buy Now318.12%Craig-Hallum
Alexander Nowak
→ $30Initiates → BuyGet Alert
03/11/2022Buy Now150.87%Morgan Stanley
Drew Ranieri
$20 → $18MaintainsOverweightGet Alert
11/15/2021Buy Now178.75%Morgan Stanley
Drew Ranieri
Reinstates → OverweightGet Alert

FAQ

Q

What is the target price for Bioventus (BVS) stock?

A

The latest price target for Bioventus (NASDAQ:BVS) was reported by Canaccord Genuity on May 8, 2024. The analyst firm set a price target for $8.00 expecting BVS to rise to within 12 months (a possible 11.58% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Bioventus (BVS)?

A

The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by Canaccord Genuity, and Bioventus maintained their buy rating.

Q

When was the last upgrade for Bioventus (BVS)?

A

The last upgrade for Bioventus Inc happened on December 7, 2023 when Canaccord Genuity raised their price target to $7. Canaccord Genuity previously had a hold for Bioventus Inc.

Q

When was the last downgrade for Bioventus (BVS)?

A

The last downgrade for Bioventus Inc happened on November 22, 2022 when Craig-Hallum changed their price target from N/A to N/A for Bioventus Inc.

Q

When is the next analyst rating going to be posted or updated for Bioventus (BVS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

Q

Is the Analyst Rating Bioventus (BVS) correct?

A

While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $7.00 to $8.00. The current price Bioventus (BVS) is trading at is $7.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch